FDA Blocked From Stopping Off-Label Fish Oil Promotion

By , Category : Health News

Disclaimer: Results are not guaranteed*** and may vary from person to person***.

Off-Label Fish Oil PromotionCiting the First Amendment, a district judge has barred the U.S. Food and Drug Administration (FDA) from stopping Amarin, an Irish pharmaceutical company, from performing off-label promotion of its fish-oil drug.

The drug in question, “Vascepa,” has-FDA approval to be marketed for treating people with high levels of triglycerides—a form of blood fat with high levels linked to heart disease. In an attempt to expand its market, Amarin later sought approval to market Vascepa to people with lower (but still high) triglyceride levels. The FDA denied permission.

Although the FDA does not permit companies to market drugs for off-label purposes, doctors are free to prescribe them for off-label use. Amarin wanted to share the results of a 2011 study with doctors since it gave “supportive but not conclusive” research that Vascepa was effective in treating coronary heart disease in low-to-high triglyceride patients. Following a series of talks with the FDA, Amarin launched the constitutional challenge.

The lawsuit is still ongoing, but the judge’s granting of preliminary relief allows Amarin to engage in “truthful and non-misleading speech promoting the off-label use” of their drug immediately. Amarin would, however, have to tell doctors that Vascepa has not been approved to treat coronary heart disease and that its risk of death has not been assessed. Although the lawsuit and the judge’s preliminary ruling are narrowly focused, it is being closely watched for any ramifications the outcome may have concerning the FDA’s power to restrict off-label promotions for other drugs in the future.

The FDA, for its part, has warned that Amarins “frontal assault” on the drug approval framework risks bringing the country to a pre-1962 era of regulation when companies had no requirement to prove drugs to be safe or effective for the advertised use. Amarin’s own view is that the lawsuit is based on the idea that well-informed doctors can make enhanced treatment decisions.

The ruling is still preliminary and the FDA has 60 days to make an appeal.

Sources for Today’s Article:
Coyle, D., “Irish Drug Company Amarin Defeats FDA in US Lawsuit,” The Irish Times web site, August 7, 2015; http://www.irishtimes.com/business/health-pharma/irish-drug-company-amarin-defeats-fda-in-us-lawsuit-1.2310282.
Johnson, C., “FDA Barred from Restricting Company’s Promotion of Fish-oil Drug,” Washington Post web site, August 7, 2015; http://www.washingtonpost.com/news/wonkblog/wp/2015/08/07/fda-barred-from-restricting-companys-promotion-of-fish-oil-drug/.

Sign up for the latest health news, tips and special product offers with our daily Free e-Letters, the Doctors Health Press e-Bulletin and the Health eTalk with the Bel Marra Doctors.

Opt-in by entering your e-mail address below and clicking submit. Your e-mail will never be shared, sold or rented to anyone for promotional or advertising purposes, and you can unsubscribe easily at any time.

Yes, I’m opting in for the FREE Doctors Health Press e-Bulletin and
Health eTalk with the Bel Marra Doctors:

Adrian Newman, B.A.

About the Author, Browse Adrian's Articles

Adrian has been working in the information publishing world since 1997. But when it comes to health information, he’s a self-admitted late bloomer. A couch potato since pre-school, Adrian was raised on TV, video games and a lifestyle that led to childhood obesity that followed him well into adulthood. But when he hit his forties, he decided enough was enough. He had a family to take care of and his days of overeating, under-exercising and inactivity were going to lead... Read Full Bio »